SAB Biotherapeutics (SABS) Guggenheim SMID Cap Biotech Conference summary

Company overview and platform

• Clinical-stage biotech focused on autoimmunity, developing a human anti-thymocyte globulin using a proprietary transchromosomic cow platform.

• Platform produces specifically targeted human IgG, avoiding safety issues of animal-derived products.

• Only company globally with this technology, leveraging robust immune response and plasma volume from cows.

Platform advantages and technology

• Cows are genetically engineered to produce only human IgG, enabling targeted antibody production.

• High plasma yield and robust immune response make cows ideal for scalable production.

• Existing dairy infrastructure supports efficient operations.

Recent clinical data and findings

• Phase I trial in healthy volunteers tested single ascending doses up to 2.5 mg/kg.

• Demonstrated T-cell exhaustion and Treg sparing, replicating efficacy mechanisms of Thymoglobulin without serum sickness or immunogenicity.

• No long-term lymphodepletion observed; lymphocyte levels normalized within three days.

• Transient lymphopenia is a lab finding, not clinically significant.